STEROID INFUSION IMPLANT TESTED AT HSS (Orthopedics This Week)
http://www.psivida.com/ “pSivida is a leading provider of miniaturized, sustained-release drug delivery products”
The pSivida Corporation and Hospital for Special Surgery, New York, are initiating an investigation into a sustained–release implant to treat severe knee osteoarthritis. According to the August 1, 2016 news release, the implant device is designed to provide long-term pain relief for patients with severe knee osteoarthritis. Physicians will implant the device into the non-articulating part of the knee during an outpatient procedure.
Researchers will evaluate the implant for six months. Pain relief after a single treatment is expected to extend for up to one year or more. The open-label, single-dose, safety and tolerability study will assess the ability of the implant to administer dexamethasone. Each of the six patients in the study will have the device implanted in one knee. Each week, investigators will assess change from baseline in mean of pain intensity scores at rest, with activity and at night through 24 weeks.
“We believe this product has the potential to provide long-term pain relief and to contribute to improved joint function for patients with severe osteoarthritis, which can delay knee replacement surgery,” said Robert N. Hotchkiss, M.D.,medical director of clinical research at Hospital for Special Surgery.
“Implanting a small, secure reservoir that delivers a corticosteroid on a sustained basis directly to the knee could avoid the issues with systemic steroid delivery and repetitive knee injections. This implant, the result of the combined insights [from] HSS and the expertise of pSivida, has the potential to create a paradigm shift in a variety of conditions.”